Generic Drugs

Senate Report Exposes Big Pharma’s Profiteering at Americans’ Expense

February 14, 2024 - On February 6, 2024, the United States Senate's Health, Education, Labor, and Pensions (HELP) Committee published a Majority Staff Report highlighting the issue of exorbitant drug prices in the United States. It focuses on the business practices of three major pharmaceutical companies — Johnson & Johnson (J&J), Merck, and Bristol Myers Squibb (BMS). The report reveals...

Read More


More Articles

Senate Hearing Challenges Pharma CEOs on Drug Pricing

by Alivia Kaylor

In a heated Senate hearing on February 8th, the CEOs of Bristol Myers Squibb, Johnson & Johnson, and Merck faced rigorous questioning from various United States senators regarding the exorbitant...

Pfizer Sues Dexcel Pharmaceuticals Alleging Patent Infringement

by Hayden Schmidt

Early this week, Pfizer and the Scripps Research Institute announced that they would be suing Israel’s Dexcel Pharma for patent infringement affecting Vyndamax, a drug that already generated $818...

Mallinckrodt Shareholders Doubt Company Will Pay $200M Opioid Settlement

by Hayden Schmidt

United Kingdom-based Mallinckrodt is considering repeat bankruptcy as its $200 million opioid payment comes due. A Security and Exchange Commission (SEC) filing from June 5 showed that company...

Novo Nordisk Cuts Prices of Insulin Pens and Vials by Up to 75%

by Veronica Salib

By January 2024, Novo Nordisk plans to cut the prices of insulin pens and vials by up to 75%. The company is echoing strategies reported by Eli Lilly earlier this month, attempting to widen access to...

Pfizer Considers Potential $40B Seagen Acquisition

by Hayden Schmidt

Pfizer Inc is reportedly in talks to buy the cancer drugmaker Seagen Inc after a potential acquisition by Merck last year fell through. In August 2022, it was reported that Merck was considering a $40...

FDA Data Shows That 125 Drugs Are Currently in Short Supply

by Hayden Schmidt

On October 12, the FDA reported a shortage of amphetamine aspartate, more commonly known as Adderall. This was one of seven shortages reported by the FDA since the beginning of the month, and it joins...

Novartis Is Losing Its Battle Against a Generic Drug for MS

by Hayden Schmidt

On Thursday of last week, the US Supreme Court (SCOTUS) allowed the launch of generic versions of Novartis’s Gilenya, siding with China’s HEC Pharm Co and other pharmaceutical companies...

Understanding Differences between Generic, Brand Name, Biosimilars

by Veronica Salib

Every day patients, payers, and providers must navigate the pharmaceutical industry to obtain and deliver treatment. Unfortunately, the industry is full of language and nuances that make this process unnecessarily difficult. When providers...

California Allots $100 Million to Produce Insulin, Improving Access

by Veronica Salib

According to the CDC, patients with type one diabetes have a pancreas that produces no or little insulin. To properly manage the disease, many patients take insulin. With the price of insulin rising,...

$354M BARDA Contract for Pharmaceutical Manufacturing Goes Unfulfilled

by Hayden Schmidt

In May 2020, Phlow Corp. received $354 million to bring inexpensive generic pharmaceutical manufacturing to the United States. At the time, it was one of the largest coronavirus-era contracts to be...

Antitrust Lawsuit against Generic Pharmaceutical Companies Is Amended

by Hayden Schmidt

A Pennsylvania Judge barred plaintiffs in an antitrust lawsuit from recouping substantial financial penalties in their case against a group of pharmaceutical companies. Judge Cynthia Rufe will not...

Sandoz Launches Generic Drug Combination for Ocular Hypertension

by Samantha McGrail

Sandoz recently launched its generic drug combination eyedrop, brimonidine tartrate/ timolol maleate ophthalmic solution 0.2%/0.5%, to lower eye pressure in patients with ocular...

Sandoz Acquires Drug Delivery Device Company to Boost Pipeline

by Samantha McGrail

Sandoz, a Novartis division, recently acquired a UK-based medical and drug delivery device company, Coalesce Product Development Limited.   Through the terms of the agreement, Sandoz...

CHMP Recommends Pfizer, Biohaven’s Generic Drug for Migraine Attacks

by Samantha McGrail

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently adopted a positive opinion for Pfizer and Biohaven’s generic drug to treat migraine...

2020 Drug Price Increase Driven by Generic Drugs, Biosimilars

by Samantha McGrail

The estimated drug price inflation rate for this year is expected to have a moderate price increase, according to Vizient’s 2022 Pharmacy Market Outlook. The Vizient Pharmacy Program looked at...

Specialty Drugs Accounted for Half of Medicaid Spending in 2020

by Samantha McGrail

Specialty drugs accounted for 51.4 percent of the net cost in Medicaid and 1.3 percent of utilization in 2020, according to a Magellan Health trend report. The Medicaid Pharmacy Trend Report looked at...

Pfizer, Biohaven Commercialize Generic Drug For Migraine Attacks

by Samantha McGrail

Pfizer and Biohaven Pharmaceuticals recently collaborated to commercialize rimegepant, a generic drug used to treat migraine attacks, in markets outside of the US. Commercialized as Nurtec ODT in the...

Placebo Elicits Same Side Effects As Cholesterol-Lowering Statins

by Samantha McGrail

An American Heart Association study recently found that patients taking cholesterol-lowering statin medication and patients taking a placebo reported the same side effects.  Specifically,...

Amazon Launches Its Own Pharmacy, Prescription Delivery Service

by Samantha McGrail

Amazon is moving into the pharmacy business by launching its own online pharmacy and prescription delivery services, the company recently announced. The first offering, Amazon Pharmacy, allows...

Recent Articles